Replimune Group (NASDAQ:REPL) Shares Down 6.6% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price traded down 6.6% on Tuesday . The company traded as low as $10.16 and last traded at $10.17. 382,397 shares were traded during trading, a decline of 45% from the average session volume of 695,592 shares. The stock had previously closed at $10.89.

Analysts Set New Price Targets

A number of research firms have recently issued reports on REPL. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. JPMorgan Chase & Co. raised their price objective on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Jefferies Financial Group increased their price target on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets raised their price target on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research note on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $17.29.

Replimune Group Trading Down 4.4 %

The business has a 50 day moving average of $12.37 and a two-hundred day moving average of $11.18. The firm has a market cap of $712.22 million, a P/E ratio of -3.41 and a beta of 1.28. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Analysts predict that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Insider Activity at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of REPL. Charles Schwab Investment Management Inc. increased its position in Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after acquiring an additional 52,498 shares during the period. Geode Capital Management LLC raised its position in Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the last quarter. Barclays PLC lifted its holdings in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after buying an additional 98,791 shares during the period. LMR Partners LLP raised its position in shares of Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after acquiring an additional 48,920 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after buying an additional 53,313 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.